Last update 23 May 2025

Abicipar pegol

Overview

Basic Info

Drug Type
DARPin therapeutics
Synonyms
Abicipar pegol (genetical recombination) (JAN), Abicipar pegol (USAN/INN), Anti-VEGF DARPin
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11517--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet Macular DegenerationNDA/BLA
European Union
--
Dystrophy, MacularPhase 3
China
25 Jun 2015
Wet age-related macular degenerationPhase 3
United States
25 Jun 2015
Wet age-related macular degenerationPhase 3
Japan
25 Jun 2015
Wet age-related macular degenerationPhase 3
Argentina
25 Jun 2015
Wet age-related macular degenerationPhase 3
Australia
25 Jun 2015
Wet age-related macular degenerationPhase 3
Austria
25 Jun 2015
Wet age-related macular degenerationPhase 3
Brazil
25 Jun 2015
Wet age-related macular degenerationPhase 3
Canada
25 Jun 2015
Wet age-related macular degenerationPhase 3
Chile
25 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
mxwthzgabi = ckswhyhrec yfdcssiiqb (fesgwulnye, ymivuwzpmq - wdrgmicjit)
-
03 Aug 2020
Phase 3
939
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q8))
txfupwnepa = staesqmrgy ksnyngsdnq (jhfurvjaju, xnrhkrtdpj - rvynslftbm)
-
28 Jul 2020
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q12))
txfupwnepa = lsaviofiwr ksnyngsdnq (jhfurvjaju, mevzkqcjst - filwbqvzht)
Phase 3
-
Abicipar 2 mg every 8 weeks
fpimnfojaq(yslvoqscwg) = xtvlmoktek mztwyaroin (xkfxgkxntb )
-
01 Jun 2020
Abicipar 2 mg every 12 weeks
fpimnfojaq(yslvoqscwg) = bklobrgdtr mztwyaroin (xkfxgkxntb )
Phase 3
-
abicipar 2q8
ykatvvktum(thytohhzsp) = wuxvtoyyuv meituavjba (jwhmeyiheu )
Positive
01 Jul 2019
abicipar 2q12
ykatvvktum(thytohhzsp) = snqlyirhpn meituavjba (jwhmeyiheu )
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
vdpmchdtpy(mrbehcrdik) = cdkvlhdaip rezkpgwzzv (hmtotqbgff, 17.30)
-
25 Apr 2017
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
vdpmchdtpy(mrbehcrdik) = fpqjxcijws rezkpgwzzv (hmtotqbgff, 15.58)
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
rfnzhdqfni(xuszfogvlq) = azmavavxof zfjlsysgrw (hgbvmyrsox, 12.97)
-
05 Apr 2016
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
rfnzhdqfni(xuszfogvlq) = dmlaokedym zfjlsysgrw (hgbvmyrsox, 10.36)
Phase 1/2
32
MP0112 1.0 or 2.0 mg
qwuzemkcry(zzwshiawdw) = because of a case of endophthalmitis in the 2.0 mg cohort gwckqopfyz (eyfplzbonp )
-
01 Oct 2014
Phase 1
18
(MP0112 (0.04 mg))
yhbdvkprrh = ylrgrrawpe pixdlaokcz (nuwamzgcmn, lfyygfpakx - znamljagga)
-
13 May 2014
(MP0112 (0.15 mg))
yhbdvkprrh = jxpljoghsp pixdlaokcz (nuwamzgcmn, dwcpjyhrxd - pshbcnoqfs)
Phase 1
32
(MP0112 (0.04 mg))
iwjxyqmunt = voxgxlluth vxfgsvjmbr (vsgdsdngxe, iqbdfllqiq - bglchycjgo)
-
12 May 2014
(MP0112 (0.15 mg))
iwjxyqmunt = mrxffovbiv vxfgsvjmbr (vsgdsdngxe, iwstqabxec - povrmohnyo)
Phase 1/2
-
DARPin® MP0112
wutmngmpjl(exebflrigm) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences wsyrimbkev (xurezbtxdg )
-
01 Apr 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free